Drug Safety update
October 2023: Isotretinoin (Roaccutane▼): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age
April 2023: Isotretinoin (Roaccutane▼): new safety measures to be introduced in the coming months, including additional oversight on initiation of treatment for patients under 18 years
July 2021: Oral retinoid medicines (isotretinoin, alitretinoin, and acitretin): temporary monitoring advice during coronavirus (COVID-19) pandemic
August 2020: Isotretinoin (Roaccutane▼): reminder of important risks and precautions
June 2019: Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
March 2019: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?
October 2017: Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido
December 2014: Isotretinoin: risk of serious skin reactions.
December 2014: Isotretinoin for severe acne: who should prescribe it
December 2014: Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders
December 2014: Oral retinoids: pregnancy prevention—reminder of measures to minimise teratogenic risk
Topical retinoids are recommended for comedonal acne; they may initially cause redness of the skin and skin peeling. This usually settles with time.
Pregnancy - retinoids (systemic or topical) should be avoided.
Severe acne requires oral antibiotics and referral for consideration of isotretinoin for treatment failures.
Oral isotretinoin (Roaccutane®) is a toxic and teratogenic drug and can only be prescribed by Consultant Dermatologists.